HIV-1 gp120 mini V3 loop and uses thereof
The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies.
1. A polypeptide comprising SEQ ID NO: 1.
2. The polypeptide of claim 1 further comprising one or more glycans.
3. The polypeptide of claim 2 wherein a glycan is Man 8/9 GlcNAc 2 .
4. The polypeptide of claim 3 wherein the glycan is attached to N332.
5. The polypeptide of claim 2 a glycan is Man 5 GlcNAc 2 .
6. The polypeptide of claim 5 wherein the glycan is attached to N301.
7. A composition comprising the polypeptide of claim 1 , wherein the composition elicits an anti-HIV-1 antibody.
8. A method for eliciting an immunogenic or immunological response, wherein the method comprises administering the composition of claim 7 to an animal that generates antibodies to the composition, collecting a sample from the animal comprising the antibodies, and detecting the presence of anti-HIV antibodies in the sample.
9. A method of generating an anti-HIV immune response comprising administering to an animal capable of eliciting antibodies the composition of claim 7 .
10. A method for detecting anti-HIV antibodies comprising contacting a sample suspected of having such antibodies with the composition of claim 7 and detecting antigen-antibody binding activity using ELISA.